KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Revenue (2016 - 2025)

Pacira BioSciences has reported Revenue over the past 16 years, most recently at $196.9 million for Q4 2025.

  • Quarterly results put Revenue at $196.9 million for Q4 2025, up 5.14% from a year ago — trailing twelve months through Dec 2025 was $726.4 million (up 3.63% YoY), and the annual figure for FY2025 was $726.4 million, up 3.63%.
  • Revenue for Q4 2025 was $196.9 million at Pacira BioSciences, up from $179.5 million in the prior quarter.
  • Over the last five years, Revenue for PCRX hit a ceiling of $196.9 million in Q4 2025 and a floor of -$492.2 million in Q4 2022.
  • Median Revenue over the past 5 years was $168.0 million (2022), compared with a mean of $132.3 million.
  • Biggest five-year swings in Revenue: crashed 409.18% in 2022 and later surged 136.82% in 2023.
  • Pacira BioSciences' Revenue stood at $159.2 million in 2021, then crashed by 409.18% to -$492.2 million in 2022, then soared by 136.82% to $181.2 million in 2023, then grew by 3.32% to $187.3 million in 2024, then grew by 5.14% to $196.9 million in 2025.
  • The last three reported values for Revenue were $196.9 million (Q4 2025), $179.5 million (Q3 2025), and $181.1 million (Q2 2025) per Business Quant data.